PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

Review Gastroenterology & Hepatology

Burden of Pancreatic Cancer: From Epidemiology to Practice

Natalia Khalaf et al.

Summary: Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide with 432,242 related deaths in 2018. Research on risk factors is crucial for prevention, surveillance, and treatment of pancreatic cancer.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer

Junjie Huang et al.

Summary: Through data analysis of 48 countries, increasing trends in pancreatic cancer incidence and mortality were observed, especially among women and populations over the age of 50, as well as among younger individuals. More preventive efforts are recommended for these populations.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Oncology

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation

Anne Patsouris et al.

Summary: The RUBY study evaluated the efficacy of rucaparib in HER2-negative metastatic breast cancer patients, indicating that some patients without germline BRCA1/2 mutation could benefit from PARP inhibitors. However, additional biomarkers are needed to selectively identify potential responders.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Biology

Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study

Francisco Quinonero et al.

Summary: PARP-1 plays a significant role in gastrointestinal tumors, being highly expressed in tumor cells and cell populations with CSC characteristics. Inhibitors of PARP-1 can increase apoptosis and reduce the formation of 3D tumorspheres.

JOURNAL OF BIOSCIENCES (2021)

添加到收藏夹

Article Oncology

Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation

Waisse Waissi et al.

Summary: This study demonstrates that combining proton therapy, gemcitabine, and olaparib has a better efficacy compared to using any of the treatments alone, significantly inhibiting tumor growth. Whole transcriptome analysis showed dynamic changes in gene expression after chemoradiation and identified a classifier for gemcitabine response.

CANCERS (2021)

添加到收藏夹

Article Oncology

Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model

Yanyan Jiang et al.

Summary: The study found that the addition of olaparib increased the therapeutic index of hemithoracic radiation in a mouse model of lung cancer, enhancing anti-tumour efficacy without increasing lung toxicity.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

BRCA mutated pancreatic cancer: A change is coming

Michael N. Rosen et al.

Summary: Pancreatic cancer is a deadly disease, especially for patients with BRCA mutations. These mutation carriers have some effective treatment options, including platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Review Oncology

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

Mariana Paes Dias et al.

Summary: PARP inhibitors have shown success in treating certain cancer patients, but most will develop resistance to these inhibitors, prompting the need for novel treatment strategies. Current research efforts are focused on finding ways to overcome resistance mechanisms.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study

Kevin Doello et al.

Summary: The study demonstrated that sodium selenite has a strong antitumor effect against pancreatic cancer and enhances the efficacy of gemcitabine, showing potential for future clinical trials.

CANCERS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

The role of PARP inhibitors in BRCA mutated pancreatic cancer

Jeffrey Chi et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that is resistant to chemotherapy and radiation therapy. Tumors with DNA damage repair defects like BRCA mutations respond better to platinum-based chemotherapies. PARP inhibitors, such as olaparib, have shown promising results in treating advanced PDAC and may lead to improved patient outcomes.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

添加到收藏夹

Review Cell Biology

PARP and PARG inhibitors in cancer treatment

Dea Slade

GENES & DEVELOPMENT (2020)

添加到收藏夹

Review Cell Biology

Stem cells in cancer initiation and progression

Jeevisha Bajaj et al.

JOURNAL OF CELL BIOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Heng Zhu et al.

MOLECULAR CANCER (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Stergios Boussios et al.

DRUGS IN R&D (2020)

添加到收藏夹

Article Chemistry, Medicinal

Bengamide Analogues Show A Potent Antitumor Activity against Colon Cancer Cells: A Preliminary Study

Beatriz Garcia-Pinel et al.

MARINE DRUGS (2020)

添加到收藏夹

Review Chemistry, Medicinal

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

Nur Aininie Yusoh et al.

CHEMMEDCHEM (2020)

添加到收藏夹

Review Oncology

PARP inhibition in treatment of pancreatic cancer

Pascal Hammel et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2020)

添加到收藏夹

Review Cell Biology

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance

Maddison Rose et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy

Daniel Harrision et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells

Rachel L. Mintz et al.

BIOENGINEERING & TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Oncology

PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer

Yu Jiang et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Review Oncology

Postoperative surveillance of pancreatic cancer patients

L. A. Daamen et al.

EJSO (2019)

添加到收藏夹

Review Oncology

PARP Inhibition in Cancer: An Update on Clinical Development

Esha Sachdev et al.

TARGETED ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Cancer statistics, 2019

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

添加到收藏夹

Article Oncology

Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance

Fei Xu et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Article Cell & Tissue Engineering

Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy

Awad Jarrar et al.

STEM CELLS (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

Lauren Montemorano et al.

ONCOTARGETS AND THERAPY (2019)

添加到收藏夹

Review Oncology

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

Francisco Quinonero et al.

CANCER BIOLOGY & MEDICINE (2019)

添加到收藏夹

Article Oncology

Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas

Yue Bi et al.

GYNECOLOGIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Xiaoting Lin et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes

Andrew McGuigan et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells

Qiang Wang et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2017)

添加到收藏夹

Editorial Material Dermatology

Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay

Ayman Grada et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)

添加到收藏夹

Article Oncology

Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro

Xiaorong Mao et al.

MOLECULAR MEDICINE REPORTS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Chandra Bhushan Prasad et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Veliparib for the treatment of ovarian cancer

Stefano Bogliolo et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Katsuhiko Uesaka et al.

LANCET (2016)

添加到收藏夹

Article Oncology

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Dong Wang et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Betty K. Samulitis et al.

CANCER BIOLOGY & THERAPY (2015)

添加到收藏夹

Article Oncology

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib

Xueli Yang et al.

ONCOLOGY LETTERS (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib

Marine Gilabert et al.

PLOS ONE (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway

L. Adesso et al.

ONCOGENE (2013)

添加到收藏夹

Article Oncology

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Oncology

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

Joana M. Senra et al.

MOLECULAR CANCER THERAPEUTICS (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells

Michael S. Goldberg et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

添加到收藏夹

Article Oncology

Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis

David Martin-Oliva et al.

CANCER RESEARCH (2006)

添加到收藏夹

PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

相关参考文献

导出引文

分享论文